A new form of booster vaccine could it be administered against Covid-19? If no study has yet proven the effectiveness of its vaccine, the Chinese manufacturer CanSino Biologics, based in the north of the country, has received authorization from the Chinese authorities. for his inhalable vaccine to be administered as an emergency booster dose.
In theory, this form of vaccine provides several advantages over intramuscular vaccines. While the latter often require storage at very low temperatures and trained healthcare personnel to administer them, inhalable vaccines can be administered through disposable devices.
“The inhalable vaccines may also induce a localized immune response targeting mucosal surfaces where pathogens enter, instead of a systemic immune response, without specifically targeting the re infection of the pathogen, as do intramuscular vaccines”says the scientific journal Nature. Scientists in several countries have been working on these vaccines that can be injected through the nose for several months. Indeed, this means of injection would present great hope: block the infection more quicklythe nose being an entry point for the coronavirus.
In Franceremember that a French research team (University of Tours / INRAE) is working on a vaccine candidate that can be administered in the nose. Clinical trials could start in 2022. The idea being to inject the vaccine directly into the nasal cavities, or directly at the entry point of the virus, where the initial stage of the infection takes place and where the virus multiplies.
CanSino’s vaccine will be administered via a sprayer, without the need to be injected and easier to store. However, the firm has not yet announced a date for making this adenovirus vaccine available to the general public.
How effective is this vaccine?
No international publication has yet validated the efficacy of the CanSino Biologics vaccine. Nevertheless, Chinese scientists conducted a clinical trial on adult patients who had already received two doses of the Chinese CoronaVac vaccine. They were divided into three groups of approximately 140 people: the first received a booster dose of CoronaVac, the second received a low dose of the inhalable vaccine and the last in received a heavy dose.
According to the results, published in a preprint – not yet peer-reviewed – patients who received three doses of CoronaVac had virtually no antibodies against the Omicron BA.1 variant while those in both groups of the inhaled vaccine showed © levels of antibodies against Omicron deemed “detectable”. They have nevertheless decreased over the weeks. Its effectiveness however has not been tested against BA.5, currently majority in France at 95%.
Could this vaccine arrive one day in France?
According to immunologist Stéphane Paul, an arrival of the injectable vaccine is France is judged “unlikely“, he indicated to the Parisian. No Chinese vaccine has yet been authorized in Europe and CoronaVac has been under continuous review by the European Medicines Agency (EMA) since May 2021. € the reverse, no international vaccine has been authorized in China. Eight locally developed vaccines have so far been approved by the Chinese government.
Source :
- CanSinoBIO’s Convidecia Air receives approval in ChinaCanSinoBIO, September 2022
